Being obese or overweight carries increased risk factors for cardiotoxicity from anthracyclines and sequential anthracyclines and trastuzumab, according to a recent study. The meta-analysis included 8,745 patients with breast cancer who were treated with anthracyclines and sequential anthracyclines and trastuzumab. Researchers found:
• The combination of obesity and being overweight was significantly associated with a greater risk of developing cardiotoxicity after anthracyclines and a sequential anthracyclines and trastuzumab regimen in patients with breast cancer.
• Pooled odds ratio for cardiotoxicity was:
◊ 1.38 (n=9,745) for overweight or obesity (BMI >25 kg/m2).
◊ 1.47 (n=2,615) for obesity.
◊ 1.15 (n=2,708) for overweight.
Citation: Guenancia C, Lefebvre A, Cardinale D, et al. Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: A systematic review and meta-analysis. [Published online ahead of print July 25, 2016]. doi:10.1200/JCO.2016.67.4846.
Must Reads in Breast Cancer
Gender Images & Social Expectations in BC Diagnosis, Cancer; ePub 2018 Sep 24; Kim, Glassgow, et al
Predicting Mammography Adherence by Income Level, Women’s Health Issues; ePub 2018 Aug 8; Gathirua-Mwangi, et al
Estrogen-alone Therapy & Invasive Breast Cancer, Menopause; ePub 2018 May 7; Shufelt, et al
Missed Breast Cancers in High Risk MRI Screening, Breast Cancer Res Treat; ePub 2018 Jan 31; Vreemann, et al